Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, SEPT. 08, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SELLAS LIFE SCIENCES GROUP, INC. (SELLAS OR THE COMPANY) (NASDAQ: SLS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SELLAS LIFE SCIENCES GROUP, INC. - SLS

NEW YORK, SEPT. 3, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SELLAS LIFE SCIENCES GROUP, INC. ("SELLAS" OR THE "COMPANY") (NASDAQ: SLS).

- THREE POSTERS TO HIGHLIGHT PRECLINICAL ACTIVITY OF SLS009 (TAMBICICLIB) ACROSS PATIENT-DERIVED KRAS MUTANT ORGANOID MODELS OF PANCREATIC CANCER  - STUDIES CONDUCTED IN COLLABORATION WITH THE UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH - NEW YORK, SEPT. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT THREE ABSTRACTS EVALUATING SLS009 (TAMBICICLIB), A POTENT, SELECTIVE CDK9 INHIBITOR, IN PRECLINICAL MODELS OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) HAVE BEEN ACCEPTED FOR POSTER PRESENTATION AT THE AACR CONFERENCE ON PANCREATIC CANCER: NEW FRONTIERS IN BIOLOGY AND THERAPEUTIC DEVELOPMENT.

SELLAS LIFE SCIENCES TO PRESENT PRECLINICAL DATA ON SLS009 IN PANCREATIC DUCTAL ADENOCARCINOMA AT THE 2026 AACR CONFERENCE ON PANCREATIC CANCER

NEW YORK, SEPT. 01, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SELLAS LIFE SCIENCES GROUP, INC. (SELLAS OR THE COMPANY) (NASDAQ: SLS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

- FINAL ANALYSIS OF PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA TO BE CONDUCTED FOLLOWING THE 80 TH EVENT - - 28 PATIENTS ENROLLED IN PHASE 2 TRIAL OF SLS009 IN NEWLY DIAGNOSED FIRST-LINE AML; TOPLINE DATA EXPECTED IN Q4 2026 - - STRONG PRECLINICAL INDICATIONS OF EFFICACY OF SLS009 IN ADVANCED PANCREATIC CANCER RESISTANT TO RAS INHIBITORS, CLINICAL DEVELOPMENT PREPARATIONS ONGOING - - $138.3 MILLION IN CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2026 - NEW YORK, AUG. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A CORPORATE UPDATE. THE SECOND QUARTER WAS AN IMPORTANT PERIOD OF EXECUTION FOR SELLAS AS WE CONTINUED TO ADVANCE BOTH OF OUR LEAD CLINICAL PROGRAMS, GPS AND SLS009, SAID ANGELOS STERGIOU, MD, SCD H.C.

SELLAS LIFE SCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW YORK, MAY 14, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT ANGELOS STERGIOU, MD, SCD H.C., PRESIDENT AND CHIEF EXECUTIVE OFFICER OF SELLAS, WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: 2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM FORMAT: CORPORATE PRESENTATION AND FIRESIDE CHAT DATE AND TIME: TUESDAY, MAY 19, 2026, AT 2:00 PM ET LOCATION: NEW YORK, NY WEBCAST LINK: CLICK HERE A.G.P.

SELLAS LIFE SCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

 CONTRACT RESEARCH ORGANIZATION FOR THE PIVOTAL PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML) INFORMED THE COMPANY THAT 78 EVENTS HAVE OCCURRED IN THE TRIAL AS OF MAY 11, 2026; SELLAS REMAINS BLINDED TO TRIAL OUTCOMES   FINAL ANALYSIS OF REGAL TRIAL OF GPS IN AML TO BE CONDUCTED FOLLOWING THE 80 TH EVENT   ONGOING DOSING OF PATIENTS IN PHASE 2 TRIAL OF SLS009 IN NEWLY DIAGNOSED FIRST LINE AML   $107.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2026; ADDITIONAL $7.5 MILLION IN PROCEEDS RECEIVED IN Q2 2026 TO DATE THROUGH WARRANT EXERCISES  NEW YORK, MAY 12, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE. THE FIRST QUARTER OF 2026 MARKED AN IMPORTANT PERIOD FOR SELLAS AS WE CONTINUED TO EXECUTE ACROSS OUR CLINICAL PROGRAMS WHILE PREPARING FOR THE ANTICIPATED PIVOTAL PHASE 3 REGAL TRIAL DATA READOUT, SAID ANGELOS STERGIOU, MD, SCD H.C.

SELLAS LIFE SCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

 CONTINUED ADVANCEMENT OF PIVOTAL PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML) - FINAL ANALYSIS UPON REACHING 80 EVENTS 

SELLAS LIFE SCIENCES REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- PRECLINICAL DATA SHOW THAT SLS009 LOWERS THE APOPTOTIC THRESHOLD IN AML CELLS BY SUPPRESSING CRITICAL SURVIVAL PATHWAYS - - PRECLINICAL DATA SHOW THAT SLS009 LOWERS THE APOPTOTIC THRESHOLD IN AML CELLS BY SUPPRESSING CRITICAL SURVIVAL PATHWAYS -

SELLAS LIFE SCIENCES TO PRESENT PRECLINICAL DATA HIGHLIGHTING POTENT ACTIVITY OF SLS009 IN AML AT THE 2026 AACR CONFERENCE

- STUDY TO ENROLL 80 PATIENTS UNLIKELY TO BENEFIT FROM VENETOCLAX/AZACITIDE (AZA/VEN) THERAPY IN THE US AND EUROPE - - SELLAS' PREDICTIVE BIOMARKER AND AI ASSISTED PRECISION MEDICINE MODELS TO BE UTILIZED - - TOPLINE DATA EXPECTED IN Q4 2026 

SELLAS LIFE SCIENCES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN NEWLY DIAGNOSED FIRST-LINE AML TRIAL OF SLS009

NEW YORK, JAN. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (SELLAS'' OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT WITH IMPACT-AML, A EUROPEAN COLLABORATIVE INITIATIVE DEDICATED TO ADVANCING INNOVATIVE TREATMENTS FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML). UNDER THE AGREEMENT, THE IMPACT-AML NETWORK WILL CONDUCT A CLINICAL STUDY EVALUATING SLS009, A HIGHLY SELECTIVE CDK9 INHIBITOR, ENABLING ACCESS TO MULTIPLE EUROPEAN CLINICAL SITES AND PATIENTS.

SELLAS Life Sciences Group, Inc.

SLS

Price

Financial Reports

No items found.

Press Releases

SELLAS Life Sciences Group, Inc.

SLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SLS